|
FDA Maintains Lead in Cancer Drug Approvals, New Study Finds
The FDA continues to approve cancer drugs more quickly than the European Medicines Agency (EMA), clearing them in about half of the time regardless of the drugs’ designation, according to a recent study.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives